Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M, Barreira-Díaz A, Salcedo MT, Callejo-Pérez A, Muñoz-Couselo E, Iranzo P, Ortiz-Velez C, Cedrés S, Díaz-Mejía N, Ruiz-Cobo JC, Morales R, Aguilar-Company J, Zamora E, Oliveira M, Sanz-Martínez MT, Viladomiu L, Martínez-Gallo M, Felip E, Buti M. Riveiro-Barciela M, et al. Among authors: munoz couselo e. Aliment Pharmacol Ther. 2024 Apr;59(7):865-876. doi: 10.1111/apt.17898. Epub 2024 Feb 7. Aliment Pharmacol Ther. 2024. PMID: 38327102
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I, Martin-Liberal J, García-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, Azaro A, Vieito M, Braña I, Mur G, Ros J, Mateos J, Villacampa G, Berché R, Oliveira M, Alsina M, Elez E, Oaknin A, Muñoz-Couselo E, Carles J, Felip E, Rodón J, Tabernero J, Dienstmann R, Perez-Lopez R, Garralda E. Matos I, et al. Clin Cancer Res. 2020 Apr 15;26(8):1846-1855. doi: 10.1158/1078-0432.CCR-19-2226. Epub 2019 Nov 22. Clin Cancer Res. 2020. PMID: 31757877
Toxicities from immunotherapy: From clinical trials to real-world clinical practice.
Riveiro-Barciela M, Trallero-Araguás E, Martínez-Valle F; Vall d’Hebrón Group for the study of Immunotherapy immune-related adverse events; Vall d’Hebrón Committee for management of Immunotherapy immune-related adverse events. Riveiro-Barciela M, et al. Med Clin (Barc). 2020 Dec 24;155(12):541-547. doi: 10.1016/j.medcli.2020.06.057. Epub 2020 Aug 28. Med Clin (Barc). 2020. PMID: 32868034 Review. English, Spanish.
The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate.
Aceituno L, Bañares J, Ruiz-Ortega L, Callejo-Pérez A, Muñoz-Couselo E, Ortiz-Velez C, Díaz-Mejía N, Barreira-Díaz A, Carreras MJ, Farriols A, Buti M, Riveiro-Barciela M. Aceituno L, et al. Front Med (Lausanne). 2022 Jul 15;9:916213. doi: 10.3389/fmed.2022.916213. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35911389 Free PMC article.
Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice.
Sabaté Gallego M, Pérez Esquirol E, Garcia Doladé N, Vidal Guitart X, Carreras Soler MJ, Farriols Danés A, Felip E, Braña I, Carles Galceran J, Morales Barrera R, Muñoz-Couselo E, Agustí Escasany A. Sabaté Gallego M, et al. Front Med (Lausanne). 2022 Aug 22;9:891179. doi: 10.3389/fmed.2022.891179. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36072949 Free PMC article.
74 results